October 3, 2025
PRISM BioLab Announces Patent Grant for Novel Bicyclic PepMetics® Compounds
PRISM BioLab was granted a new patent covering a novel class of bicyclic PepMetics® compounds on...
Read More
October 3, 2025
Notice of Termination of Collaboration and Licensing Agreement with Servier
We would like to announce that PRISM BioLab and Servier have mutually agreed to terminate the...
Read More
August 2, 2025
Notice of Termination of Collaboration and Licensing Agreement with Eli Lilly and Company
We would like to announce that PRISM BioLab and Eli Lilly and Company have mutually agreed...
Read More
June 9, 2025
PRISM BioLab Announces Patent Acquisition for PepMetics® Technology Library Compounds
PRISM BioLab is pleased to announce that we obtained a patent for our novel compound library...
Read More
May 23, 2025
Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
TOKYO, Japan, 23 May 2025: -- PRISM BioLab, Co. Ltd. , a leading discovery and development...
Read More
May 14, 2025
Announcement: Investor Relations Seminar for Individual Investors
CEO Dai Takehara will participate in the "103rd IR Seminar for Individual Investors" hosted by Logmi...
Read More
May 10, 2025
Featured in Nikkei Biotech
Nikkei Biotech has published an interview with our CEO Dai Takehara, and our Director/Head of R&D...
Read More
April 14, 2025
Featured in The Nikkei
PRISM BioLab has been featured in The Nikkei (Nihon Keizai Shimbun). "PRISM BioLab and AI Drug...
Read More
April 13, 2025
PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets
TOKYO, Japan, 14 April 2025 -- PRISM BioLab, Co. Ltd., a leading discovery and development biotechnology...
Read More
March 13, 2025
Announcement: Guest Appearance on Radio NIKKEI 1’s The Money – Thursday, Hideaki Sakurai’s Kabutetsu
Our CEO, Takehara, recently appeared on Radio NIKKEI 1’s The Money – Thursday, Hideaki Sakurai’s Kabutetsu....
Read More